[Skip to content]

National Research Ethics Service
Search our Site
Health Research Authority
.
REC Reference
07/H0712/85
REC Name
St Mary's REC
Name of establishment responsible for the bank
St Mary's Hospital NHS Trust
Short title
TB Immunology Group Research Tissue Bank
Title of Bank
TB Immunology Group Research Tissue Bank
Contact Point Name/Address
Permission to publish contact details not yet received
Contact Point Phones
Permission to publish contact details not yet received
Types of Sample from living
We will be collecting and storing tissue samples from all areas of the human body that can become infected with Mycobacterium tuberculosis. This material will include sputum, urine, pleural fluid, pleural biopsies, pericardial fluid, ascitic fluid, cerebrospinal fluid, broncoalveloar lavage specimins, transbronchial lung biopsies, open lung biopsies, renal biopsies, adrenal biopsies, liver biopsies, gastric and bowel biopsies, laryngeal biopsies, muscle biopsies, bone marrow biopsies, lymph node biopsies and skin biopsies. We will also be collecting blood samples to detect immune responses to the bacterium and to perform genetic analysis (please see 'Summary of Research' document for full details). The specimens will be supplied fresh and are perishable in nature. Their likely deterioration time is measured in hours. They will be analysed immediately or frozen in the Research Tissue Bank to be studied at a later date. There will be approximately 400 samples accured annually and these will all be used for the purposes of our research. Samples may be sent to collaborating labs for further analysis (as indicated in the patient consent forms). We will not destroy any samples (unless at the donor's request) during the lifetime of the initial licence for the Research Tissue Bank (five years).

Data will be collected and stored (anonymously) for linking with the samples. This data will be demographic (including age, sex, ethnicity and country of origin) and medical (including BCG vaccination status, pre-existing conditions and co-existing morbidity). The data will be derived from direct contact with the patient via a questionnaire at the time of consenting them for the tissue sample to be taken. It may also be derived from medical notes which will be read by the research team (after written consent from the patient). This data will be stored anonymously on computers used by all members of the TB Immunology Group. The data will remain the property of the Research Tissue Bank.
Types of Sample from deceased
The sites of collection and information regarding storage and use of specimens are the same as detailed in section B1 of this application.

Data collection will be the same as detailed in section B1. The data may also be collected from the deceased's relatives via a questionnaire (after full written and informed consent).
Intended use of Samples
As explained in our document 'Research Programme Summary' (which is enclosed with this application), the aims of the TB Immunology group are to develop and rigorously evaluate new tools for improved screening, diagnosis and prevention of TB. The existence of a Research Tissue Bank will be of immense importance in helping us achieve these goals.

The creation of the Research Tissue Bank will be advertsied on an email list to members of the Wright Fleming Institute of Infection and Immunity and to members of staff at St. Mary's Hospital. It will be explained that we will be storing tissue and data relating to TB immunology and we will invite clinicians to contact us if they have any potential donors who may be interested.
Research to be undertaken
The research will be carried out by the Tuberculosis Immunology Group and will therefore focus on tuberculosis and related granulomatous disease e.g. sarcoid and atypical mycobacteria infection. It will be translational and 'basic' in nature. We will be working on tissue samples to try to discover novel aspects of host immune mechanisms underlying TB infection. For example we will use tissue samples from patients with active tuberculosis and compare them to patients with latent (slient) tuberculosis to try to discover a difference in their immunological markers. This may help develop an immunological test to distinguish betwen active and latent disease. Please refer to our 'Summary of Research Programme' document for further detailed information.
Decision
Favourable Opinion
HTA licence number
not yet received
Date published 19/05/2011